No Data
No Data
Express News | Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
S&P 500 Futures Climb In Premarket Trading; Neurocrine Biosciences, Equitable Holdings Lead
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $22
Roivant Sciences Price Target Raised to $22.00/Share From $20.00 by Piper Sandler
Roivant Sciences Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $22